Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateQuince Therapeutics, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Flagged at $30.82 at 11:00 AM on Oct 09, then ran to $37.00 +20% that session.
The high is the session peak after our first alert, not a realized trade. Not investment advice.
Why is QNCX moving? Get the live chart, real-time scanner alerts, the catalyst behind the move, and full due diligence on QNCX - free.
Our scanner flagged $QNCX 10 times in the last 30 days. Create a free account to track $QNCX, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on QNCX from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for QNCX today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystDISCLAIMERS The information in thisReported – 18% due to poor aqueous solubility, high molecular weight, extensive first‑pass metabolism, variable gastrointestinal conditions, food effects, and P‑glycoprotein-mediated efflux Sirolimus (Rapamycin) prescribingReported N = 4 Δ 6MWD (m) +81.3 +67.4 Δ VO2 Max (% Predicted) +5.4% +6.7% % Δ PVR (exercise) -25.5% -35.3% % Δ PVR (supine) -28.1% -33.9% % Δ NT-proBNP -29.0% -28.8% Δ FVC (% Predicted) +4.8% +1.8%Reported FC II and III; PVR >4, PH-ILD Group 3; symptomatic despite stable background rx PRIMARY ENDPOINTS Δ PVR SECONDARY ENDPOINTS Δ 6MWD; Incidence of Clinical Worsening; Time to Clinical Worsening, % of pts maintain or improve WHO functional, from an SEC filing. Read it →Latest filing144Notice of proposed insider sale (144)Oct 21, 2026 · 4 days ago* Institutional ownership was unavailable, so float is insider-deduped only.
The company is cleared to issue new shares on demand, but has not yet. Size not stated in the filing.
Some filings did not state a size, so these are floors.
Active shelf on file — the company can issue new shares on demand (valid ~3 years)
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on QNCX from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for QNCX today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
The live QNCX price and chart above update during market hours (4 AM to 8 PM ET).
The QNCX Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged QNCX 10 times in the last 30 days.
QNCX (Quince Therapeutics, Inc. Common Stock) trades on XNAS, with a market cap of about $32M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge QNCX for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$QNCX discussion
Sign in to ask a question or join the discussion.